Search Prime Grants

W81XWH2220074

Cooperative Agreement

Overview

Grant Description
Development and early clinical evaluation of a novel mechanism-of-action antimalarial.
Awardee
Eisai
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Cambridge, Massachusetts 021402325 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Analysis Notes
Amendment Since initial award the total obligations have decreased 100% from $3,837,258 to $0.
Eisai was awarded Cooperative Agreement W81XWH2220074 from Defense Health Agency in September 2022 with work to be completed primarily in Cambridge Massachusetts United States. The grant has a duration of 2 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 7/27/23

Period of Performance
9/15/22
Start Date
9/14/24
End Date
81.0% Complete

Funding Split
$0.0
Federal Obligation
$0.0
Non-Federal Obligation
$0.0
Total Obligated
100% Federal Funding
0% Non-Federal Funding

Transaction History

Modifications to W81XWH2220074

Additional Detail

Award ID FAIN
W81XWH2220074
SAI Number
None
Award ID URI
None
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
RGWZFJJC9DD3
Awardee CAGE
9EFF5
Performance District
MA-05
Senators
Edward Markey
Elizabeth Warren

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $3,837,258 100%
Modified: 7/27/23